NewAmsterdam: Obicetrapib significantly reduces p-tau217 in ApoE4 carriers in BROADWAY

NewAmsterdam Pharma Co N.V.

p-tau217 reduced in full analysis set (p=0.0019, n=1,515) and ApoE4 carriers (p=0.0215, n=367).
ApoE4/E4 carriers showed 20.48% mean p-tau217 reduction vs placebo (p=0.010).
Favorable trends observed in NFL, GFAP, p-tau181, and Aβ42/40 biomarkers.
Safety in BROADWAY overall was comparable to placebo; AD analysis not independently evaluated.
Company plans to discuss results with regulators and explore next steps for AD program.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.